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ABSTRACT
Background    Tanjin is an herbal medicine made from 
the root of salvia miltiorrhiza. It is predominantly given 
to arteriosclerotic patients as a supplement to ameliorate 
the clinical symptoms of cardiovascular diseases. In 
China, tanjin is used frequently in combination treat-
ment for hypercholesterolemia. Thus, there is a high 
probability of combination of tanjin and statins in these 
arteriosclerotic patients. This study investigated the 
interaction between tanjin and rosuvastatin.
Methods    We performed a randomized single-blind, 
two-period crossover clinical trial on six healthy male 
volunteers. Volunteers were administered rosuvastatin 
with placebo or a tanjin-containing drug randomly. 
The blood samples were collected before drug admin-
istration, and at 0.5, 1, 1.5, 2, 4, 8, and 12 hours after 
administration. Lymphocytes were isolated from blood 
samples before and 12 hours after drug administration 
to measure mRNA. As an animal experiment, an in situ 
intestinal injection with portal vein sampling model was 
used to examine the interaction between tanjin and ro-
suvastatin during the absorption phase. Rosuvastatin or 
rosuvastatin combined with tanjin solution was injected 
into the intestine. After injection, blood from the portal 
vein was collected and the concentration of rosuvastatin 
was measured by LC/MS/MS analysis. A portion of the 
intestine and liver from the rats was collected and stored 
at –80°C for mRNA measurement.
Results    In the clinical trial, co-administration of tan-
jin decreased the maximum plasma concentration (Cmax) 
of rosuvastatin by 26.85% compared with rosuvastatin 
alone, and also decreased the area under the plasma 
concentration-time curve of rosuvastatin from 0 to 12 h 
(AUC0–12) by 19.43%. The relative expression of BCRP 
and OATP mRNA in human lymphocytes was increased 
by co-administration of tanjin. In the animal experiment, 
co-administration of tanjin extract reduced the concen-
tration of rosuvastatin to 84.4, 64.4, and 50.0% at 15, 30, 
and 45 minutes, respectively. The tanjin-containing drug 
had a similar effect to tanjin extract. Furthermore, tanjin 
significantly reduced the absorption of rosuvastatin and 
the inhibitory effects lasted for at least 24 hours. Tanjin 
increased the relative expression of BCRP mRNA in the 
intestine, but it did not change the expression of OATP. 
Moreover, the concentration of rosuvastatin in the portal 
vein and systemic blood was reduced. In the liver, tanjin 
increased both BCRP and OATP mRNA expression, 
which was consistent with the results from human lym-
phocytes.
Conclusion    The clinical trial and animal experiment 
revealed that tanjin can significantly reduce the absorp-
tion of rosuvastatin. This interaction occurred, at least, 
at the absorption phase in the small intestine due to the 
enhanced efflux transport. Thus, as tanjin and rosuvasta-
tin were found to interact, their combination needs to be 
paid attention to.
Key words    absorption; drug interactions; herbal medi-
cine; pharmacokinetics; rosuvastatin
Tanjin (TJ, the roots of Salvia miltiorrhiza) is a tra-
ditional herbal medicine that is widely used to treat 
cardiovascular diseases, such as angina pectoris, myo-
cardial infarction, and stroke,1, 2 in China and the clinical 
symptoms of hypertension, such as headache, dizziness, 
and palpitations, in Japan. Some TJ-containing drugs 
are sold as class 2 OTC (over the counter) drugs in stores 
or online, and many TJ supplements are considered to 
be beneficial to prevent or ameliorate cardiovascular 
diseases for the healthy population and hypercholesterol-
emia patients. In recent years, TJ has been used to treat 
hypercholesterolemia.3-5 Statins, a kind of HMG-CoA 
(3-hydroxy-3-methyl-glutaryl-coenzyme A) reductase 
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inhibitor, are well-known lipid-lowering medications 
that have been found to reduce cardiovascular disease 
(CVD) and mortality in people with a high risk of car-
diovascular disease.6 Statins have some rare but severe 
adverse effects, such as neuropathy, pancreatic, liver 
dysfunction, and muscle damage,7 especially in the case 
of excessive dosing. It is important to explore whether 
there are drug interactions between TJ and statins, and 
if there are, what role the absorption phase plays in this 
interaction. 
 A previous study reported the interaction between 
TJ and rosuvastatin (RST) in rats.8 However, the figure 
in this report showed a decreased plasma concentration 
of RST, whereas the text stated that the concentration 
was increased by co-administration of TJ. We were con-
fused by this inconsistency and performed a preliminary 
study in rats to clarify whether the concentration of RST 
was increased or decreased by TJ. As a result, the con-
centration of RST was found to have decreased. We then 
investigated the drug interaction in vivo in humans.
 In this study, we examined the influence of TJ on 
the pharmacokinetics of RST in six healthy volunteers. 
After the clinical study, we evaluated the drug inter-
action in rat to confirm the inhibitory effects of TJ on 
RST absorption using an in situ intestinal injection with 
portal vein sampling (IIPS) model.9
MATERIALS AND METHODS
Clinical trial
This clinical trial was registered in the UMIN Clinical 
Trials Registry under the Receipt No. R000029950, and 
was conducted in accordance with the ethical princi-
ples established in the Declaration of Helsinki and the 
Ethical Guidelines for Clinical Research. The final pro-
tocol was approved by the ethics committee of Tottori 
University, Faculty of Medicine in Japan (#1703B088).
 Physical examinations and laboratory tests for vital 
signs were conducted at screening. Volunteers with 
abnormalities in laboratory tests or drug hypersensitivity 
were excluded from this study. Six healthy volunteers 
(male, mean age of 21) were finally selected and written 
informed consent was obtained from all participants. 
The demographic characteristics of each group are listed 
in Table 1 and the experimental process is described in 
Fig. 1.
 The six volunteers were divided into two equal 
groups (3 persons in each group). The study had a ran-
domized, single-blind, two-period crossover design. One 
of the groups received a single dose of RST (CRESTOR 
Tablet 5 mg, rosuvastatin calcium salt, p.o.) with placebo 
(lactose, 2.5 g) as treatment I. The other group received 
a single dose of RST (5 mg, p.o.) with a TJ-containing 
drug (Kangenkaryu, 2.5 g, Iskra Industry, Tokyo, Japan) 
as treatment II. Kangenkaryu are granules that contain 
TJ as a main component. After a washout period of 6 
days, the treatments were exchanged. Venous blood 
samples were collected at 0, 0.5, 1, 1.5, 2, 4, 8, and 12 
hours after oral administration. The blood samples were 
centrifuged at 4000 rpm for 15 minutes to obtain the 
plasma and stored at –30°C for analysis. The concentra-
tion of RST was measured by LC/MS/MS. The blood 
samples at 0 and 12 hours after drug administration 
were collected, and lymphocytes were isolated using 
a Lymphoprep Tube (Alere Technologies AS, Oslo, 
Norway) according to the separation procedure.
Table 1. Group demographics and characteristics
Group 1 
(n = 3, Treatment I + II)
Group 2 
(n = 3, Treatment II + I)
Age (year) 21.3 ± 1.5 [20, 23] 20.7 ± 0.6 [20, 21]
Height (cm) 173.3 ± 3.2 [171, 177] 171.3 ± 2.1 [169, 173]
Weight (Kg) 66.3 ± 2.5 [64, 69] 64.3 ± 1.5 [63, 66]
BMI (body 
mass index) 22.1 ± 0.2 21.9 ± 0.6
The data are shown as the mean ± standard deviation. The min-
imum and maximum of each characteristic are shown in square 
brackets. Treatment I: RST (single dose of 5 mg) with placebo for 
TJ (2.5 g). Treatment II: RST (single dose of 5mg) with TJ (single 
dose of 2.5 g). RST, rosuvastatin; TJ, tanjin.
Fig. 1. Flow diagram of the clinical trial. Each group contained 
3 volunteers, and between periods 1 and 2, there was a washout 
period of 7 days. Treatment I was administration of RST (single 
dose of 5 mg, p.o.) with placebo for TJ (2.5 g), whereas treatment 
II was administration of RST (single dose of 5 mg, p.o.) with TJ (2.5 
g). RST, rosuvastatin; TJ, tanjin.
Animal experiment
Animals and drugs
The experimental protocol was approved by the ethics 
committee on animal experiments at Tottori University 
(#15-Y-52 and #16-Y-12) and the experiments were 
carried out in accordance with the guidelines for animal 
experiments of the same facility. Twenty-one 8-week old 
rats were purchased from Shimizu Laboratory Supplies 
of Kyoto in Japan. RST calcium salt was purchased 
from Wako Pure Chemical Industries, Ltd (No.186-
02731). The TJ-containing drug (Kangenkaryu) and TJ 
tablets were used in the animal experiment. TJ tablets 
made from TJ extract were purchased from Shanghai 
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Leiyunshang Pharmaceutical (Shanghai, China). 
 RST was dissolved in distilled water to make a 
solution with a concentration of 0.083 mg/mL. Two TJ 
tablets were dissolved in 24.5 mL distilled water, and 
2.05 mg of RST calcium was added to make mixed 
solution A. One package (2.5 g) of the TJ-containing 
drug was dissolved in 40.8 mL of distilled water and 3.41 
mg of RST was added to make mixed solution B. These 
solutions were stored at 4°C. 
 In the acute experiment, rats were divided into three 
groups: the A group (n = 6), which received RST at 0.83 
mg/kg and a TJ tablet (0.367 g/kg equivalent to crude 
TJ), the B group (n = 6), which received RST and the TJ-
containing drug, and the C group (n = 6), which received 
RST alone at 0.83 mg/kg. 
 In the chronic experiment, 25 rats were divided into 
four groups. The A group (n = 7) and B group (n = 7) 
were pre-treated with TJ by gavage for 7 days, whereas 
the C group (n = 6) and D group (n = 5) were pre-treated 
with saline by gavage for 7 days. On the following day 
of the surgical experiment, A and C groups were inject-
ed with RST alone, and B and D groups were injected 
with RST and TJ. The experimental procedure of blood 
collection was the same as that for the acute experiment. 
IIPS rat model analysis
The surgical procedures for the IIPS rat model were 
described previously.9 In brief, the rats were anesthe-
tized by pentobarbital sodium (50 mg/kg) and 1 mL of 
heparin was intraperitoneally injected. Then, an incision 
was made along the linea alba of the abdomen to expose 
the intestines and portal vein. Next, 3 mL of the RST 
or RST + TJ solution was injected into the intestine by 
syringe, and a catheter was inserted into portal vein to 
collect 0.3–0.4-mL blood samples at 15, 30, 40, and 
45 minutes after injection. After 2–3 mL of blood was 
collected from the heart, the rats were sacrificed by 
abdominal arterial bleeding. The blood samples were 
centrifuged at 4000 rpm for 15 minutes at 4°C and the 
plasma samples were stored at –80°C for analysis. 
LC/MS/MS analysis
The detailed method for LC/MS/MS analysis was 
described in our previous study.9 RST was dissolved in 
methanol to make stock solution at concentrations of 
1000, 500, 100, 50, 10, 5, and 1 ng/mL. Control plasma 
was diluted 10-times using water. Nine hundred µL of 
diluted plasma was added to 100 µL of 1000, 500, 100, 
50, 10, 5, or 1 ng/mL RST in 100 µL of methanol. 
 Plasma with triple the volume of methanol was cen-
trifuged at 15000 rpm for 5 min at 4°C, and 200 µL of 
the supernatant was diluted 10-times using water. One 
hundred and eighty µL of the diluted solution was added 
to 20 µL of methanol. These 200-µL samples were used 
to measure the concentration of RST by LC/MS/MS 
(AB SCIEX QTRAP 5500 LC/MS/MS System, SCIEX, 
Tokyo, Japan).
RT-PCR
RST is transported by organic-anion-transporting poly-
peptide (OATP) 1B110-12 and is mainly effluxed by breast 
cancer resistance protein (BCRP)13-15 in the intestine 
and liver. In rats, the homologous gene of OATP 1B1 
is OATP 1b2.16 Thus, after measurement of the plasma 
concentration of RST, we also measured the relative 
expression of OATP and BCRP mRNA in human lym-
phocytes, and the rat intestine and liver.
 Total RNA was extracted from lymphocyte, liver, 
and small intestine samples by TRIzol reagent (Promega, 
Carlsbad, CA) according to the instruction manual. 
Real-time fluorescence PCR (polymerase chain reaction) 
was carried out with LightCycler Nano (Roche, Basel, 
Switzerland) using KAPA SYBR FAST One-Step kit. 
The primers for BCRP, OATP1b2, and GAPDH were 
synthesized by Fasmac Company (Atsugi, Japan), and 
listed in Tables 2 and 3. The relative expression of 
mRNA was calculated by the double delta Ct analysis 
method. The expression of GAPDH mRNA was used as 
an internal standard reference.
Table 2. PCR primer sequences for the clinical trial
Gene Primer
OATP1B1 Forward 5’-AGTCCAGATTGCACCAAACC-3’
Reverse 5’-TGACAAGCATACCTGGGACA-3’
BCRP Forward 5’-AGCTGCAAGGAAAGATCCAA-3’
Reverse 5’-TGCCCATCACAACATCATCT-3’
GAPDH Forward 5’-CAATGACCCCTTCATTGACC-3’
Reverse 5’-GACAAGCTTCCCGTTCTCAG -3’
BCRP, breast cancer resistance protein; GAPDH, glyceraldehyde-
3-phosphate dehydrogenase; OATP, organic anion transporting 
polypeptide. 
Table 3. The PCR primer sequences for the animal ex-
periment
Gene Primer
OATP1b2 Forward 5’-CAGTGGCAGGCTTAACAACCT-3’
Reverse 5’-GGATCCCATGTGTTCGTTGAG-3’
BCRP Forward 5’-CCACTGGAATGCAAAATAGAG-3’
Reverse 5’-CCTCATAGGTAGTAAGTCAGACACA-3’
GAPDH Forward 5’-AGGGCTGCCTTCTCTCTTGAGT-3’
Reverse 5’-AACTTGCCGTGGGTAGAGTCA-3’
BCRP, breast cancer resistance protein; GAPDH, glyceraldehyde-
3-phosphate dehydrogenase; OATP, organic anion transporting 
polypeptide. 
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the area under the curve (AUC) of RST in each subject 
between the two treatments (RST + TJ / RST) are shown 
in Figs. 3a and b.
 The ratios of Cmax were all below 1-fold and the 
95% confidence interval was 0.7 ± 0.09 (Fig. 3a). The 
ratios of AUC were also below 1-fold and the 95% con-
fi dence interval was 0.77 ± 0.08 (Fig. 3b). These results 
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Fig. 2. The plasma concentration of RST in the volunteers. At 0, 
0.5, 1, 1.5, 2, 4, 8, and 12 hours after RST administration (closed 
circle, n = 6) or RST + TJ administration (open circle, n = 6). The 
Tmax was at 4 hours after drug administration. TJ reduced the 
blood concentration of RST throughout the observation period. 
*P < 0.05 vs. group RST. Tmax, time of peak concentration; RST, 
rosuvastatin; TJ, tanjin.
Fig. 4. The concentration of RST in portal vein and systemic 
blood in the acute experiment. The concentrations of RST at 15, 
30, and 40 minutes in portal vein blood and heart blood after drug 
injection were measured. A group (open circle, n = 6) received 
RST (0.83 mg/kg) and TJ tablets (0.367 g/kg equivalent to crude 
medicine), the B group (cross mark, n = 6) received RST and the 
TJ-containing drug, and the C group (closed circle, n = 6) were 
received RST alone at 0.83 mg/kg. Both TJ tablets and the TJ-
containing drug signifi cantly reduced the concentration of RST at 
15, 30, and 40 min after injection. *P < 0.05 vs. C group. Heart: 
RST concentration in the systemic blood collected at 40 minutes 
after drug injection. RST, rosuvastatin; TJ, tanjin.
Statistical analysis 
The data are expressed as the mean ± standard devia-
tion. Statistical comparisons were made using the two 
independent samples t-test with SPSS 11.0J. A value of 
P < 0.05 was considered signifi cant.
RESULTS
 TJ reduced the systemic concentration of RST in 
the clinical trial 
The plasma concentrations of RST after drug adminis-
tration are shown in Fig. 2. TJ reduced the concentration 
of RST throughout the observation period.
 Ratios of the maximum concentration (Cmax) and 
Fig. 3. The ratios of RST Cmax and AUC in combination with TJ 
to RST single administration. Color circles indicate ratios of AUC 
and Cmax in each subject, and black circles indicate the mean ratio 
and 95% confi dence interval. (ratio is calculated by RST + TJ / 
RST alone). The geometric mean ratios of AUC and Cmax were 
0.77 ± 0.08 and 0.7 ± 0.09, respectively. AUC, the area under the 
plasma RST concentration-time curve; Cmax, maximum plasma 
drug concentration; RST, rosuvastatin; TJ, tanjin.
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Fig. 5. The concentration of RST in the chronic experiment. The 
concentrations of RST at 15, 30, and 45 minutes after drug injec-
tion in the chronic experiment were measured. A group (open cir-
cle, n = 7) and B group (cross mark, n = 7) were pre-treated with 
TJ by gavage for 7 days, whereas the C group (closed circle, n = 
6) and D group (closed square, n = 5) were pre-treated with saline 
by gavage for 7 days. On the experiment day, the A and C groups 
were injected with RST alone, and B and D groups were injected 
with RST and TJ. Pre-treatment with TJ for 7 days reduced the 
blood concentration of RST when comparing the A and C groups. 
*P < 0.05 vs. C group. RST, rosuvastatin; TJ, tanjin. 
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Fig. 6. The relative expression ratio of BCRP and OATP in human lymphocytes from each subject. The ratio is calculated by after drug 
administration / before drug administration. The 6 subjects are indicated as a to f. *P < 0.05 by t-test. Closed bar indicates RST alone, and 
open bar indicates RST + TJ. BCRP, breast cancer resistance protein; OATP, organic-anion-transporting polypeptide; RST, rosuvastatin; 
TJ, tanjin. 
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Fig. 7. The relative expression of BCRP and OATP mRNA in the intestine and liver. Treatment with TJ for 7 days increased the expression 
of BCRP mRNA in the intestine and liver, and increased the expression of OATP mRNA in the liver. The expression of OATP mRNA 
in intestine was not changed after TJ treatment. The relative expression of BCRP mRNA in the intestine (a) and liver (b). The relative 
expression of OATP mRNA in the intestine (c) and liver (d). *P < 0.05 by t-test. BCRP, breast cancer resistance protein; OATP, organic-
anion-transporting polypeptide; RST, rosuvastatin; TJ, tanjin. 
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demonstrated that TJ can significantly reduce the Cmax 
and AUC of RST.
TJ reduced the absorption of RST in the animal ex-
periment
The interaction between TJ and RST in the absorption 
phase was also evaluated in the IIPS rat model. As 
shown in Fig. 4, both TJ tablets and the TJ-containing 
drug reduced the concentration of RST at 15, 30, and 40 
minutes after oral administration compared with RST 
alone. Therefore, in the following experiment, we only 
used the TJ-containing drug as a representative of TJ. 
We measured the systemic plasma concentration of RST 
in the blood of the heart, and found that the concentra-
tion of RST was reduced by the combination of TJ early 
after administration. The differences in the systemic 
concentration of RST suggested similar inhibitory 
effects of TJ, consistent with the results of the clinical 
trial.
 In the acute experiment, the concentration of RST 
was reduced significantly in both the TJ tablet group and 
TJ-containing drug group. There was no difference be-
tween TJ tablets and the TJ-containing drug in their in-
fluence on the absorption of RST. Thus, in the following 
chronic experiment, only the TJ-containing drug was 
used to estimate the interaction between TJ and RST.
 As shown in Fig. 5, the A and B groups were 
pre-treated with TJ for 7 days, whereas the C and D 
groups were pre-treated with saline. The A and C groups 
were injected with RST alone, and B and D groups were 
injected with RST + TJ. On comparison of A with C and 
B with D, the concentration of RST was significantly 
reduced by TJ. By comparing A and B groups, TJ was 
demonstrated to inhibit the absorption of RST and the 
inhibitory effects of TJ lasted for at least one day. 
Relative mRNA expression of transport proteins
The mRNA expression ratio (after drug administration 
/ before drug administration) in human lymphocytes of 
six subjects (a–f) and average data are shown in Fig. 6. 
The expression ratios of BCRP and OATP were reduced 
(below 1.00) in most subjects after administration of 
RST, while the expression ratios of BCRP and OATP 
were increased after administration of TJ + RST, and the 
average of expression ratio increased significantly after 
administration of RST + TJ. 
 In the animal study, there was low BCRP expres-
sion in the intestine relative to the reference value for 
GAPDH mRNA; however, the expression of BCRP 
was increased significantly by TJ in both the intestine 
and liver (Figs. 7a and b). On the other hand, OATP 
expression was increased by TJ in the liver but not in the 
intestine (Figs. 7c and d). 
DISCUSSION
TJ was originally used to treat vascular disease accord-
ing to ancient Chinese medical documents. As HMG-
CoA reductase is the key enzyme in the production of 
cholesterol, statins (HMG-CoA reductase inhibitors) 
are widely used to treat hypercholesterolemia, which 
is associated with cardiovascular disease.17 However, 
statins cause some rare but severe adverse effects such as 
muscle damage,18 myopathy and rhabdomyolysis 19-22 and 
liver damage.23, 24 Therefore, the combination of TJ and 
statins has emerged in recent years for hyperlipidemia 
treatment in China.25 Several studies investigated this 
combination in animal models.26 Although the combina-
tion of drugs may be beneficial and reduce side effects, 
the risk of adverse drug interactions may increase. 
 In this study, we investigated the interaction of TJ 
and RST in healthy volunteers. The plasma concentra-
tion of RST was reduced by co-administration of TJ 
compared with RST alone. The mean Cmax and AUC 
were decreased by 26.85% and 17.81%, respectively. 
RST is different from other statins in that almost all 
other statins are metabolized by CYP3A and have a 
marked first-pass effect.27, 28 However, RST is different 
and most RST is eliminated in feces without being 
metabolized 29; therefore, the impact of CYP3A on RST 
metabolism is negligible. The concentration of RST in 
the RST + TJ group at 1, 1.5, and 2 hours after drug 
administration was significantly reduced compared with 
that in the RST alone group, and the concentrations 
continuously decreased after peak concentrations and 
there is no significant decrease between the two groups. 
This suggests that the interaction between TJ and RST 
mainly occurs at the absorption phase, and there are 
almost no effects of the elimination phase on this drug 
interaction. Based on the results of the clinical trial, we 
speculated that absorption of RST plays a key role in the 
interaction between RST and TJ. To confirm this spec-
ulation, we used the IIPS rat model to examine whether 
this interaction occurred during intestinal absorption in 
rats. As described in our previous study, the IIPS model 
is used to investigate only the effects of absorption 
excluding other influencing elements such as the gastric 
emptying rate and intestinal motility. We confirmed that 
the concentration of RST in the portal vein was reduced 
by co-administration of TJ in both the acute and chronic 
experiments. In the chronic experiment, after pre-
treatment with TJ for 7 days, the plasma concentration of 
RST was decreased even in the RST alone group. This 
demonstrated that the inhibitory effects of TJ last for at 
least 24 hours. 
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 Next, we measured the relative mRNA expression 
levels of BCRP and OATP1b2 in the intestine of rats 
after TJ administration for 7 days, and found that the 
expression of BCRP was increased by TJ, whereas that 
of OATP, which functions in influx transport, was not 
changed. Increased BCRP expression in the intestine 
was able to reduce the concentration of RST in portal 
vein blood. This change in expression was consistent 
with the portal vein and systemic blood concentrations 
of RST. In the liver, TJ increased both OATP and BCRP 
expression levels. This may cause an increase in the 
biliary excretion of RST through hepatocytes. However, 
the acceleration of the excretion phase was not observed 
in the human trial. In this human study, only a single 
dose of RST and TJ was evaluated. And IIPS rat model 
evaluates only intestinal drug absorption. Therefore, 
further experiments are needed to determine the precise 
mechanism underlying the interaction between RST and 
TJ. 
 In conclusion, RST interacts with TJ in combination 
at least during the absorption phase in the intestine, and 
the final systemic concentration of RST is consequently 
reduced. As this will void the original intention of com-
bination therapy, this combination should be clinically 
avoided. 
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